Needham & Company Reiterates Zealand Pharma (ZEAL) at Buy, Short Bowel Syndrome Program Remains Main Value Driver
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $42.00 price target on Zealand Pharma A/S (NASDAQ: ZEAL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
